Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Anti-aging effect of extracellular vesicles from mesenchymal stromal cells on senescence-induced chondrocytes in osteoarthritis

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Contributors:
      Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB); Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM); Service de Rhumatologie CHU de Montpellier; CHU Montpellier; FOREUM Foundation for Research in Rheumatology; ANR-22-PEBI-0013,STROMAEV,From engineering of iPS-derived mesenchymal stromal cell-derived extracellular vesicles to clinical translation(2022); ANR-22-AIBB-0007,OBBI,Occitanie Biotherapy-Bioproduction Integrator : Intégrateur de Bioproduction de Vésicules Extracellulaires et d'Organoïdes en Occitanie(2022); ANR-11-INBS-0005,ECELLFRANCE,Développement d'une Plateforme Nationale pour la médecine régénératrice(2011)
    • Publication Information:
      CCSD
      Impact Journals
    • Publication Date:
      2024
    • Collection:
      Université de Montpellier: HAL
    • Abstract:
      International audience ; Age is the most important risk factor for degenerative diseases such as osteoarthritis (OA). It is associated with the accumulation of senescent cells in joint tissues that contribute to the pathogenesis of OA, in particular through the release of senescence-associated secretory phenotype (SASP) factors. Mesenchymal stromal cells (MSCs) and their derived extracellular vesicles (EVs) are promising treatments for OA. However, the senoprotective effects of MSC-derived EVs in OA have been poorly investigated. Here, we used EVs from human adipose tissue-derived MSCs (ASC-EVs) in two models of inflammaging (IL1β)-and DNA damage (etoposide)induced senescence in OA chondrocytes. We showed that the addition of ASC-EVs was effective in reducing senescence parameters, including the number of SA-β-Gal-positive cells, the accumulation of γH2AX foci in nuclei and the secretion of SASP factors. In addition, ASC-EVs demonstrated therapeutic efficacy when injected into a murine model of OA. Several markers of senescence, inflammation and oxidative stress were decreased shortly after injection likely explaining the therapeutic efficacy. In conclusion, ASC-EVs exert a senoprotective function both in vitro, in two models of induced senescence in OA chondrocytes and, in vivo, in the murine model of collagenase-induced OA.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/39578049; PUBMED: 39578049; PUBMEDCENTRAL: PMC11719114
    • Accession Number:
      10.18632/aging.206158
    • Online Access:
      https://inserm.hal.science/inserm-04888483
      https://inserm.hal.science/inserm-04888483v1/document
      https://inserm.hal.science/inserm-04888483v1/file/2024-aging-J%C3%A9r%C3%A9my.pdf
      https://doi.org/10.18632/aging.206158
    • Rights:
      http://creativecommons.org/licenses/by/ ; info:eu-repo/semantics/OpenAccess
    • Accession Number:
      edsbas.83DC42DD